Recent Developments in Gene Targeted and Immunotherapies of Parkinson's Disease
Available starting June 26, 2020
This accredited webinar is provided free of cost to all members and non-members.
Live Q&A Session
Wednesday, August 26 at 09:00 AM ET / 08:00 AM CT
Roy N. Alcalay, MD
Joseph Quinn, MD
Carlos Singer, MD
The treatment of Parkinson’s disease (PD) has thus far been restricted to symptomatic therapies. These treatments improve quality of life but do not address PD’s relentless progression.
The discovery of genetic mutations that cause or increase the risk of development of PD has opened the possibility of genetically targeted therapies with the potential of slowing or stopping the progression of specific monogenetic forms of PD. Further, the possibility that misfolded synuclein aggregation is a key pathogenetic factor in PD has culminated in ongoing trials of synuclein-targeted immunotherapies with a similar potential benefit for all forms of PD, be they genetic or sporadic.
This webinar will review the current state of affairs of clinical trials of both these types of therapies. The lectures will cover the pharmacology and recent results of relevant clinical trials, as well as their future directions.
This course is intended for neurologists interested or specializing in Movement Disorders.
- Describe the different mechanisms of action of the gene and synuclein targeted therapies of PD
- Explain the current state of development of clinical trials of both therapies
- Recognize the use of biomarkers to monitor target engagement and effect on progression of PD
- Identify future directions of these novel therapeutic modalities
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The International Parkinson and Movement Disorder Society designates this activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation.
Participants must complete an evaluation for each session they attend to receive continuing medical education credit. Your chosen session(s) must be attended in their entirety. Partial credit for individual sessions is not available.
Content Validity Statement
All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.
Faculty Financial Disclosure Information
All individuals in control of content for this webinar are required to disclose all relevant financial relationships with commercial interests as defined by the ACCME. Disclosure information is available here.